NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 50% | – | – | – |
| R&D Expenses | $2 | $3 | $3 | $3 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $7 | $7 | $7 |
| Operating Income | -$5 | -$7 | -$7 | -$8 |
| % Margin | -782.2% | – | – | – |
| Other Income/Exp. Net | -$24 | $13 | -$9 | $2 |
| Pre-Tax Income | -$29 | $7 | -$16 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$29 | $7 | -$16 | -$5 |
| % Margin | -4,511.3% | – | – | – |
| EPS | -0.84 | 0.22 | -0.67 | -0.25 |
| % Growth | -481.8% | 132.8% | -168% | – |
| EPS Diluted | -0.77 | 0.15 | -0.67 | -0.25 |
| Weighted Avg Shares Out | 29 | 29 | 24 | 22 |
| Weighted Avg Shares Out Dil | 29 | 24 | 24 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $0 | $1 | $1 |
| Depreciation & Amortization | -$1 | $0 | $0 | $0 |
| EBITDA | -$15 | $7 | -$15 | -$4 |
| % Margin | -2,341.4% | – | – | – |